IP Library Granted Patent US 12,485,281
Granted Patent B2
US 12,485,281 · App. 18/524,427 · Granted Dec 2, 2025

High frequency electrostimulation treatment for restless legs syndrome or periodic limb movement disorder

Inventor: Shriram Raghunathan (Castro Valley, CA)
Assignee: NOCTRIX HEALTH, INC.
A61N1/36057A61B5/0531A61B5/4082A61B5/4836A61N1/08A61N1/36A61N1/36014A61N1/36031A61N1/36034A61N1/36067A61N1/36139A61N1/3614A61N1/3615A61N1/36167A61B5/0022A61B5/02405A61B5/08A61B5/1114A61B5/1116A61B5/4809A61B5/4815A61B5/7264A61B5/7475A61B2562/0219A61N1/0456A61N1/0476A61N1/0484A61N1/0492A61N1/0556A61N2001/083A61N1/36021A61N1/36071A61N1/36078
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,485,281
App. No.
18/524,427
Granted
Dec 2, 2025
Kind
B2
Abstract

Restless Leg Syndrome (RLS) or Periodic Limb Movement Disorder (PLMD) can be treated using high frequency (HF) electrostimulation. This can include selecting or receiving a subject presenting with RLS or PLMD. At least one electrostimulation electrode can be located at a location associated with at least one of, or at least one branch of, a sural nerve, a peroneal nerve, or a femoral nerve. HF electrostimulation can be delivered to the subject, which can include delivering subsensory, subthreshold, AC electrostimulation at a frequency that exceeds 500 Hz and is less than 15,000 Hz to the location to help reduce or alleviate the one or more symptoms associated with RLS or PLMD. A charge-balanced controlled-current HF electrostimulation waveform can be used.

Claims (45)

1 . A method for performing neurostimulation therapy for a Restless Legs Syndrome (RLS) or Periodic Limb Movement Disorder (PLMD) patient, the method comprising:

determining a time period, during sleep, correlative to an increased likelihood of waking, the determining based on input data including at least one of patient position or movement data, a sensed heart rate, a respiration signal, sleep state information, or user input data;

activating electrostimulation or establishing or adjusting at least one electrostimulation signal parameter, upon the determining the increased likelihood of waking, the at least one electrostimulation signal parameter for treating one or more symptoms associated with RLS or PLMD using electrostimulation and controlled to stimulate n intensity subthreshold to the patient waking; and

delivering a high-frequency (HF) electrostimulation signal to a target location of the patient at a frequency between 500 Hz and 15,000 Hz using the at least one electrostimulation signal parameter.

2 . The method of claim 1 , comprising:

initiating a patient monitoring session, before the delivering the HF electrostimulation signal parameter, the patient monitoring session associated with a patient's sleeping or attempting to sleep;

wherein the determining the time period correlative to an increased likelihood of waking is based on input data collected during the patient monitoring session or within a specified time period following the delivering the HF electrostimulation signal.

3 . The method of claim 1 , wherein the establishing or adjusting the at least one electrostimulation signal parameter or determining the time period correlative to an increased likelihood of waking is based at least in part on historical data before or during previous RLS or PLMD therapy sessions corresponding with the patient.

4 . The method of claim 3 , wherein:

the historical data includes a user survey input ranking of efficacy received from the patient; and

the at least one electrostimulation signal parameter includes at least one of a start time, an intensity or a ramping duration of the electrostimulation signal.

5 . The method of claim 1 , comprising:

receiving patient leg movement data concurrently with the delivering the HF electrostimulation signal;

determining whether the patient is asleep and, based on the patient leg movement data, whether at least one RLS or PLMD symptom has decreased; and

ramping down energy of the HF electrostimulation signal toward ceasing electrostimulation based on determining that the patient is asleep and the symptom has decreased.

6 . The method of claim 5 , comprising:

monitoring, upon ramping down the energy of the HF electrostimulation signal, a patient leg movement; and

resuming delivery of the HF electrostimulation signal to the target location based on the monitored patient leg movement.

7 . The method of claim 1 , comprising determining whether a specified electrode-tissue impedance is present at the target location of the patient, the specified electrode-tissue impedance indicating an electrostimulation device is being worn by the patient in a manner suitable for delivering the HF electrostimulation signal.

8 . The method of claim 1 , wherein the at least one electrostimulation signal parameter is controlled to be perceived as subsensory by the patient.

9 . A system for performing neurostimulation therapy for a Restless Legs Syndrome (RLS) or Periodic Limb Movement Disorder (PLMD) patient, the system comprising:

a sensor circuit configured to determine a time period, during sleep, correlative to an increased likelihood of waking, the sensor circuit including at least one of a motion sensor, a sleep sensor configured to detect a sleep state, or a user input;

a controller circuit configured to initiate electrostimulation or establish or adjust at least one electrostimulation signal parameter, upon the determining the increased likelihood of waking, the at least one electrostimulation signal parameter for treating one or more symptoms associated with RLS or PLMD using electrostimulation and controlled to stimulate at an intensity subthreshold to the patient waking; and

a wearable device including an electrostimulation electronics unit including or coupled to first and second skin electrodes for delivering a high frequency (HF) electrostimulation signal to the patient at an external target body location, wherein the electrostimulation signal is delivered at a frequency of between 500 Hz and 15,000 Hz and at a current of between 5 mA and 40 mA.

10 . The system of claim 9 , wherein;

the controller circuit is configured to initiate an RLS or PLMD therapy session; and

the sensor circuit is configured to determine the time period correlative to an increased likelihood of waking based on input data collected prior to the RLS or PLMD therapy session and within a specified time frame following the initiating the therapy session.

11 . The system of claim 9 , wherein the controller circuit is configured to establish or adjust the at least one electrostimulation signal parameter or determining the time period correlative to an increased likelihood of waking is based at least in part on historical data before or during previous RLS or PLMD therapy sessions including at least one of previous timing, waveform, or efficacy data corresponding with the patient.

12 . The system of claim 11 , wherein:

the sensor circuit includes a user interface to receive historical data including a user survey input ranking of efficacy received from the patient; and

the controller circuit is configured to establish or adjust the at least one electrostimulation signal parameter including at least one of a start time, an intensity or a ramping duration of the electrostimulation signal.

13 . The system of claim 9 , wherein:

the sensor circuit includes the motion sensor for receiving leg movement data concurrently with the delivering the HF electrostimulation signal via the wearable device, wherein the sensor circuit is configured to determine whether at least one RLS or PLMD symptom has decreased based on the leg movement data; and

the controller circuit is configured to ramp down energy of the HF electrostimulation signal toward ceasing electrostimulation based on determining that the patient is asleep and the symptom has decreased.

14 . The system of claim 13 , wherein:

the sensor circuit is configured to monitor, upon ramping down the energy of the HF electrostimulation signal, a patient leg movement during the delivering the HF electrostimulation signal during a same therapy session; and

the controller circuit is configured to resume delivery of the HF electrostimulation signal to the target location based on the monitored patient leg movement.

15 . The system of claim 9 , wherein the sensor circuit includes impedance sensing circuitry configured to determine whether a specified electrode-tissue impedance is present at the target location of the patient, the specified electrode-tissue impedance indicating an electrostimulation device is being worn by the patient in a manner suitable for delivering the HF electrostimulation signal.

16 . The system of claim 9 , wherein the sensor circuit includes a heart rate variability (HRV)-based sensor.

17 . The system of claim 9 , wherein the sensor circuit includes an accelerometer.

18 . A method for performing neurostimulation therapy for a Restless Legs Syndrome (RLS) or Periodic Limb Movement Disorder (PLMD) patient, the method comprising:

determining a time period, during sleep, correlative to an increased likelihood of waking, the determining based on input data including at least one of patient position or movement data, a sensed heart rate, a respiration signal, sleep state information, or user input data;

activating electrostimulation or establishing or adjusting at least one electrostimulation signal parameter, upon the determining the increased likelihood of waking, the at least one electrostimulation signal parameter for treating one or more symptoms associated with RLS or PLMD using electrostimulation and controlled to stimulate at an intensity subthreshold to the patient waking; and

delivering a high-frequency (HF) electrostimulation signal to a target location of the patient at a frequency between 500 Hz and 15,000 Hz using the at least one electrostimulation signal parameter;

wherein the establishing or adjusting the at least one electrostimulation signal parameter or determining the time period correlative to an increased likelihood of waking is based at least in part on historical data including at least one of previous waveform or efficacy data corresponding with the patient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2024
From: RAGHUNATHAN, SHRIRAM
To: NOCTRIX HEALTH, INC.
Reel/Frame 066035/0623 →
Continuity (7)
Continuation 17534699 · Nov 24, 2021
Continuation 16416330 · May 20, 2019
Continuation 16196863 · Nov 20, 2018
Continuation PCTUS2018012631 · Jan 5, 2018
Provisional Application 62552690 · Aug 31, 2017
Provisional Application 62442798 · Jan 5, 2017
Related Publication 20240123230A1 · Apr 18, 2024
References Cited (156)
US 5487759A · Bastyr et al. · 1996 [cited by applicant]
US 5725471A · Davey et al. · 1998 [cited by applicant]
US 5759198A · Karell · 1998 [cited by applicant]
US 5995873A · Rhodes · 1999 [cited by applicant]
US 6001861A · Oertel et al. · 1999 [cited by applicant]
US 6114326A · Schueler · 2000 [cited by applicant]
US 6507757B1 · Swain · 2003 [cited by applicant]
US 6602868B2 · McBrinn et al. · 2003 [cited by applicant]
US 6958048B2 · Bonutti · 2005 [cited by applicant]
US 7403821B2 · Haugland et al. · 2008 [cited by applicant]
US 7774068B1 · Lozano · 2010 [cited by applicant]
US 7783348B2 · Gill et al. · 2010 [cited by applicant]
US 8145317B2 · Demarais et al. · 2012 [cited by applicant]
US 8365741B2 · Hennings et al. · 2013 [cited by applicant]
US 8938303B1 · Matsen · 2015 [cited by applicant]
US 8983617B2 · Chavan et al. · 2015 [cited by applicant]
US 9002477B2 · Burnett · 2015 [cited by applicant]
US 9017273B2 · Burbank et al. · 2015 [cited by applicant]
US 9205264B2 · Heruth et al. · 2015 [cited by applicant]
US 9302046B1 · Giuffrida et al. · 2016 [cited by applicant]
US 9327121B2 · Thacker et al. · 2016 [cited by applicant]
US 9387338B2 · Burnett · 2016 [cited by applicant]
US 9452287B2 · Rosenbluth et al. · 2016 [cited by applicant]
US 9474898B2 · Gozani et al. · 2016 [cited by applicant]
US 9504827B2 · DeGiorgio et al. · 2016 [cited by applicant]
US 9561371B2 · Elborno · 2017 [cited by applicant]
US 9566470B2 · Malizia · 2017 [cited by applicant]
US 9604056B2 · Starr et al. · 2017 [cited by applicant]
US 9610448B2 · Hou et al. · 2017 [cited by applicant]
US 9656070B2 · Gozani et al. · 2017 [cited by applicant]
US 9662491B2 · Yonce et al. · 2017 [cited by applicant]
US 9662502B2 · Giuffrida et al. · 2017 [cited by applicant]
US 9694181B2 · Bhadra et al. · 2017 [cited by applicant]
US 9713711B2 · Hershey et al. · 2017 [cited by applicant]
US 9737709B2 · Bachinski et al. · 2017 [cited by applicant]
US 9750933B2 · Gregory et al. · 2017 [cited by applicant]
US 9802039B2 · Palermo et al. · 2017 [cited by applicant]
US 9802041B2 · Wong et al. · 2017 [cited by applicant]
US 9808620B2 · Kent · 2017 [cited by applicant]
US 9808627B2 · Gliner et al. · 2017 [cited by applicant]
US 9814880B2 · Hershey et al. · 2017 [cited by applicant]
US 10195425B2 · Ostroff et al. · 2019 [cited by applicant]
US 10342977B2 · Raghunathan · 2019 [cited by applicant]
US 11103691B2 · Charlesworth et al. · 2021 [cited by applicant]
US 11213681B2 · Raghunathan · 2022 [cited by applicant]
US 11266836B2 · Charlesworth et al. · 2022 [cited by applicant]
US 11872399B2 · Raghunathan · 2024 [cited by applicant]
US 20030176822A1 · Morgenlander · 2003 [cited by applicant]
US 20040093093A1 · Andrews · 2004 [cited by applicant]
US 20060069415A1 · Cameron et al. · 2006 [cited by applicant]
US 20060173074A1 · Ellmen et al. · 2006 [cited by applicant]
US 20080071326A1 · Heruth · 2008 [cited by examiner]
US 20080262053A1 · Reess · 2008 [cited by applicant]
US 20090062685A1 · Bergethon et al. · 2009 [cited by applicant]
US 20090221943A1 · Burbank et al. · 2009 [cited by applicant]
US 20100049111A1 · Sorg · 2010 [cited by applicant]
US 20100160712A1 · Burnett et al. · 2010 [cited by applicant]
US 20100191311A1 · Scheiner et al. · 2010 [cited by applicant]
US 20100249637A1 · Walter et al. · 2010 [cited by applicant]
US 20110054573A1 · Mitchell · 2011 [cited by applicant]
US 20120101358A1 · Boettcher et al. · 2012 [cited by applicant]
US 20130245486A1 · Simon et al. · 2013 [cited by applicant]
US 20130325084A1 · Lee · 2013 [cited by applicant]
US 20140046423A1 · Rajguru et al. · 2014 [cited by applicant]
US 20140148725A1 · Cadwell · 2014 [cited by applicant]
US 20150066105A1 · Elborno · 2015 [cited by applicant]
US 20150165202A1 · Grandhe · 2015 [cited by applicant]
US 20150174002A1 · Burbank · 2015 [cited by examiner]
US 20150272815A1 · Kitchens · 2015 [cited by applicant]
US 20150321000A1 · Rosenbluth et al. · 2015 [cited by applicant]
US 20160030280A1 · Jones · 2016 [cited by applicant]
US 20160158542A1 · Ahmed · 2016 [cited by applicant]
US 20160310741A1 · Baru et al. · 2016 [cited by applicant]
US 20160354604A1 · Kent · 2016 [cited by applicant]
US 20170157398A1 · Wong et al. · 2017 [cited by applicant]
US 20170157404A1 · Moffitt et al. · 2017 [cited by applicant]
US 20170216586A1 · Kent · 2017 [cited by applicant]
US 20170266443A1 · Rajguru et al. · 2017 [cited by applicant]
US 20190001129A1 · Rosenbluth et al. · 2019 [cited by applicant]
US 20190083784A1 · Raghunathan · 2019 [cited by applicant]
US 20200108251A1 · Raghunathan · 2020 [cited by applicant]
US 20210100998A1 · Charlesworth et al. · 2021 [cited by applicant]
US 20210260379A1 · Charlesworth et al. · 2021 [cited by applicant]
US 20220088372A1 · Charlesworth et al. · 2022 [cited by applicant]
US 20220184397A1 · Raghunathan · 2022 [cited by applicant]
US 20220218993A1 · Charlesworth et al. · 2022 [cited by applicant]
CN 107614054A · 2018 [cited by applicant]
CN 110603073A · 2019 [cited by applicant]
CN 115087482 · 2022 [cited by applicant]
CN 117100245 · 2023 [cited by applicant]
EP 3565631 · 2024 [cited by applicant]
JP 2015512285A · 2015 [cited by applicant]
JP 2016511651A · 2016 [cited by applicant]
JP 2018526044A · 2018 [cited by applicant]
JP 2020505099A · 2020 [cited by applicant]
JP 2022188248A · 2022 [cited by applicant]
JP 2022551604 · 2022 [cited by applicant]
WO WO2015095880A2 · 2015 [cited by applicant]
WO WO2015109023A1 · 2015 [cited by applicant]
WO WO2016111863A1 · 2016 [cited by applicant]
WO WO2017023864A1 · 2017 [cited by applicant]
WO WO2018129351 · 2018 [cited by applicant]
WO WO2018129351A1 · 2018 [cited by applicant]
WO WO2021067751A1 · 2021 [cited by applicant]
“Japanese Application Serial No. 2022-163853, Response filed Mar. 27, 2024 to Notification of Reasons for Refusal mailed Oct. 3, 2023”, W English Claims, 17 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-163853, Notification of Reasons for Refusal mailed Jun. 18, 2024”, w English Translation, 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/583,990, Non Final Office Action mailed Aug. 28, 2024”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/196,863, Notice of Allowance mailed Feb. 20, 2019”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/416,330, Non Final Office Action mailed Apr. 14, 2021”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/416,330, Notice of Allowance malled Aug. 27, 2021”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/416,330, Preliminary Amendment filed Dec. 26, 2019”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/416,330, Response filed Jul. 14, 2021 to Non Final Office Action mailed Apr. 14, 2021”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/416,330, Supplemental Notice of Allowability mailed Dec. 7, 2021”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 17/062,010, Non Final Office Action mailed Jan. 7, 2021”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 17/062,010, Notice of Allowance mailed Apr. 23, 2021”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 17/062,010, PTO Response to Rule 312 Communication mailed May 20, 2021”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 17/062,010, Response filed Apr. 7, 2021 to Non Final Office Action mailed Jan. 7, 2021”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 17/241,924, Non Final Office Action mailed Jul. 12, 2021”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/241,924, Notice of Allowance mailed Oct. 28, 2021”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 17/241,924, Response filed Oct. 12, 2021 to Non Final Office Action mailed Jul. 12, 2021”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 17/534,699, Corrected Notice of Allowability mailed Nov. 8, 2023”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 17/534,699, Notice of Allowance mailed Aug. 30, 2023”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/534,699, Preliminary Amendment filed Mar. 9, 2022”. [cited by applicant]
“Chinese Application Serial No. 201880012637.9, Notification to Make Rectification mailed Sep. 10, 2019”, w/o English Translation, 1 pg. [cited by applicant]
“Chinese Application Serial No. 201880012637.9, Office Action mailed Oct. 8, 2022”, w/ English Translation, 23 pgs. [cited by applicant]
“Chinese Application Serial No. 201880012637.9, Response filed Feb. 10, 2023 to Office Action mailed Oct. 8, 2022”, w/ English claims, 37 pgs. [cited by applicant]
“European Application Serial No. 18736570.5, Communication Pursuant to Article 94(3) EPC mailed Jan. 2, 2023”, 3 pgs. [cited by applicant]
“European Application Serial No. 18736570.5, Extended European Search Report mailed Sep. 30, 2020”, 7 pgs. [cited by applicant]
“European Application Serial No. 18736570.5, Response filed Apr. 28, 2021 to Extended European Search Report mailed Sep. 30, 2020”, 26 pgs. [cited by applicant]
“European Application Serial No. 18736570.5, Response filed Jul. 11, 2023 to Communication Pursuant to Article 94(3) EPC mailed Jan. 2, 2023”, 15 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/012631, International Preliminary Report on Patentability mailed Jul. 18, 2019”, 10 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/012631, International Search Report mailed May 30, 2018”, 5 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/012631, Invitation to Pay Add'l Fees and Partial Search Report mailed Mar. 27, 2018”, 2 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/012631, Written Opinion mailed May 30, 2018”, 8 pgs. [cited by applicant]
“International Application Serial No. PCT/US2020/054006, International Search Report mailed Dec. 21, 2020”, 7 pgs. [cited by applicant]
“International Application Serial No. PCT/US2020/054006, Written Opinion mailed Dec. 21, 2020”, 8 pgs. [cited by applicant]
“Japanese Application Serial No. 2019-537068, Notification of Reasons for Refusal mailed Nov. 9, 2021”, w/ English Translation, 15 pgs. [cited by applicant]
“National Institutes of Health”, https://web.archive.org/web/20190829044030/https://allofus.nih.gov/, (Aug. 29, 2019), 6 pgs. [cited by applicant]
“Personalized medicine”, https://web.archive.org/web/20190417064230/https://www.nature.com/subjects/personalized-medicine, (Apr. 17, 2019), 5 pgs. [cited by applicant]
Allen, R P, “Restless Legs Syndrome/Willis-Eckbom Disease Pathophysiology”, Sleep Med Clin. , 10(3), (2015), 207-214. [cited by applicant]
Clemens, S, et al., “Restless leg syndrome: revisiting the dopamine hypothesis from the spinal cord perspective”, Neurology, 67, (2006), 7 pgs. [cited by applicant]
Hayashibe, Mitsuhiro, “Evoked Electromyographically Controlled Electrical Stimulation”, Frontiers in Neuroscience, (Jul. 14, 2016), 7 pgs. [cited by applicant]
Kilgore, K. L, et al., “Nerve conduction block utilising high-frequency alternating current.”, Med Biol Eng Comput., 42(3), (May 2004), 394-406. [cited by applicant]
Mitchell, U, “Medical devices for restless leg syndrome—clinical utility of the Relaxis pad”, Ther & Clin Risk Management, (2015), 1789-1794. [cited by applicant]
Qing, K, et al., “Burst-Modulated Waveforms Optimize Electrical Stimuli for Charge Efficiency and Fiber Selectivity”, IEEE Trans Neural Syst Rehabil Eng 23(6), (Nov. 2015), pp. 936-945. [cited by applicant]
Schoen, Nathan, et al., “The Use of Intraoperative Electromyogram During Spinal Cord Stimulator Placement Surgery: A Case Series”, World Neurosurgery vol. 100, (Apr. 2017), pp. 74-84. [cited by applicant]
Stewart, W, et al., “Prevalence and burden of overactive bladder in the United States”, World J Urol, 20 327-336, (2003), 11 pgs. [cited by applicant]
Vance, Carol GT, et al., “Using TENS for pain control: the state of the evidence”, Pain Management 4(3), 197-209, (2014), 13 pgs. [cited by applicant]
“U.S. Appl. No. 17/583,990, Response filed Nov. 26, 2024 to Non Final Office Action mailed Aug. 28, 2024”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 17/583,990, Notice of Allowance mailed Jan. 28, 2025”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/389,551, Preliminary Amendment filed Dec. 13, 2021”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/583,990, Preliminary Amendment filed Apr. 4, 2022”, 9 pgs. [cited by applicant]
“International Application Serial No. PCT US2020 054006, International Preliminary Report on Patentability mailed Apr. 14, 2022”, 10 pgs. [cited by applicant]
“Japanese Application Serial No. 2019-537068, Response filed May 2, 2022 to Notification of Reasons for Refusal mailed Nov. 9, 2021”, w English claims, 17 pgs. [cited by applicant]
“European Application Serial No. 20793537.0, Response to Communication pursuant to Rules 161(1) and 162 EPC Response filed Nov. 23, 2022”, 41 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-163853, Notification of Reasons for Refusal mailed Oct. 3, 2023”, w English translation, 8 pgs. [cited by applicant]